Endophenotypic studies in schizophrenia: promise and challenges.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Local gyrification index in probands with psychotic disorders and their first-degree relatives.Biological psychiatry · 2014
   Article
2. Impairment in functional capacity as an endophenotype candidate in severe mental illness.Schizophrenia bulletin · 2012
   Review
3. The evolution of drug development in schizophrenia: past issues and future opportunities.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2008
   Review
4. The DSM-V initiative "deconstructing psychosis" in the context of Kraepelin's concept on nosology.European archives of psychiatry and clinical neuroscience · 2008
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as